If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Radioligand Development for PET Imaging of β-Amyloid (Aβ)-Current Status

$63.10 plus tax (Refund Policy)

Buy Article:

Abstract:

Two of the main pathological hallmarks of Alzheimer's disease (AD) are neuritic plaques and neurofibrillary tangles. Significant evidence supports a critical and probable causative role of βamyloid (Aβ) plaque formation. Since neuroprotective treatments are typically most effective at early stages of injury, the detection and measurement of Aβ load in living brain should be performed at early and perhaps even presymptomatic stages of AD. Two primary targets of molecular imaging research with positron emission tomography (PET) are to develop surrogate markers (radioligands) for assessing disease progression and for monitoring the efficacy of developmental therapeutics. Here, we review the current status of radioligand development for PET imaging of Aβ aggregates. General structure-activity relationships have emerged, including the identification of at least three different ligand binding sites in various Aβ aggregates and recognition of the general structural requirements for ligand binding at each site. Also a few radioligands applicable to imaging Aβ plaques in living human brain with positron emission tomography (PET) have emerged, including [11C]PIB, [11C]SB- 13 and [18F]FDDNP.





Keywords: Alzheimer's disease; PET imaging; assay; radioligand; β-amyloid

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986707779313471

Affiliations: Molecular Imaging Branch,National Institute of Mental Health, National Institutes of Health, Bethesda,MD 20892, USA.

Publication date: January 1, 2007

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more